© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Feb 10, 2016, the consensus forecast amongst 4 polled investment analysts covering CTI BioPharma Corp advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 10, 2016. The previous consensus forecast advised that CTI BioPharma Corp would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 4 analysts offering 12 month price targets for CTI BioPharma Corp have a median target of 2.13, with a high estimate of 5.00 and a low estimate of 0.00. The median estimate represents a 526.66% increase from the last price of 0.3391. View Full Financials
Dividend information is not available for CTi Biopharma Corp. View Full Financials
On Nov 05, 2015, CTI BioPharma Corp reported 3rd quarter 2015 losses of -0.18 per share. This result under-performed the -0.140 loss expectation of the 3 analysts following the company but under-performed last year's 3rd quarter results by -0.21. View Full Interim Financials
|Average growth rate||-9.26 %|
CTI BioPharma Corp reported annual 2014 losses of -0.49 per share on Mar 12, 2015. View Full Annual Financials
|Average growth rate||+38.73 %|
CTI BioPharma Corp. had 3rd quarter 2015 revenues of 964.00k. This missed the 14.74m consensus estimate of the 3 analysts following the company. This was 97.56 % below the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||-52.93 %|
CTI BioPharma Corp. had revenues for the full year 2014 of 60.08m. This was 2,496.24% above the prior year's results. View Full Annual Financials
|Average growth rate||+798.75 %|